Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2 - PubMed (original) (raw)
. 2003 Oct 24;302(5645):643-6.
doi: 10.1126/science.1088759.
Affiliations
- PMID: 14576434
- DOI: 10.1126/science.1088759
Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2
Mary-Claire King et al. Science. 2003.
Abstract
Risks of breast and ovarian cancer were determined for Ashkenazi Jewish women with inherited mutations in the tumor suppressor genes BRCA1 and BRCA2. We selected 1008 index cases, regardless of family history of cancer, and carried out molecular analysis across entire families. The lifetime risk of breast cancer among female mutation carriers was 82%, similar to risks in families with many cases. Risks appear to be increasing with time: Breast cancer risk by age 50 among mutation carriers born before 1940 was 24%, but among those born after 1940 it was 67%. Lifetime risks of ovarian cancer were 54% for BRCA1 and 23% for BRCA2 mutation carriers. Physical exercise and lack of obesity in adolescence were associated with significantly delayed breast cancer onset.
Comment in
- Cancer. A risky business--assessing breast cancer risk.
Levy-Lahad E, Plon SE. Levy-Lahad E, et al. Science. 2003 Oct 24;302(5645):574-5. doi: 10.1126/science.1091465. Science. 2003. PMID: 14576407 No abstract available. - Breast cancer risks for BRCA1/2 carriers.
Easton DF, Hopper JL, Thomas DC, Antoniou A, Pharoah PD, Whittemore AS, Haile RW. Easton DF, et al. Science. 2004 Dec 24;306(5705):2187-91; author reply 2187-91. doi: 10.1126/science.306.5705.2187c. Science. 2004. PMID: 15622557 No abstract available. - Breast cancer risks for BRCA1/2 carriers.
Wacholder S, Struewing JP, Hartge P, Greene MH, Tucker MA. Wacholder S, et al. Science. 2004 Dec 24;306(5705):2187-91; author reply 2187-91. Science. 2004. PMID: 15622558 No abstract available.
Similar articles
- The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM, Offit K, Foulkes W, Robson ME, Wacholder S, Eng CM, Karp SE, Begg CB. Satagopan JM, et al. Cancer Epidemiol Biomarkers Prev. 2001 May;10(5):467-73. Cancer Epidemiol Biomarkers Prev. 2001. PMID: 11352856 - Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population.
Simchoni S, Friedman E, Kaufman B, Gershoni-Baruch R, Orr-Urtreger A, Kedar-Barnes I, Shiri-Sverdlov R, Dagan E, Tsabari S, Shohat M, Catane R, King MC, Lahad A, Levy-Lahad E. Simchoni S, et al. Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3770-4. doi: 10.1073/pnas.0511301103. Epub 2006 Feb 28. Proc Natl Acad Sci U S A. 2006. PMID: 16537453 Free PMC article. - Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM, Boyd J, Kauff ND, Robson M, Scheuer L, Narod S, Offit K. Satagopan JM, et al. Clin Cancer Res. 2002 Dec;8(12):3776-81. Clin Cancer Res. 2002. PMID: 12473589 - [Clinical and molecular diagnosis of inherited breast-ovarian cancer].
Chompret A. Chompret A. J Gynecol Obstet Biol Reprod (Paris). 2003 Apr;32(2):101-19. J Gynecol Obstet Biol Reprod (Paris). 2003. PMID: 12717301 Review. French. - Hereditary breast and ovarian cancer in Asia: genetic epidemiology of BRCA1 and BRCA2.
Liede A, Narod SA. Liede A, et al. Hum Mutat. 2002 Dec;20(6):413-24. doi: 10.1002/humu.10154. Hum Mutat. 2002. PMID: 12442265 Review.
Cited by
- How Have Massively Parallel Sequencing Technologies Furthered Our Understanding of Oncogenesis and Cancer Progression?
Onuselogu DA, Benz S, Mitra S. Onuselogu DA, et al. Methods Mol Biol. 2025;2866:265-286. doi: 10.1007/978-1-0716-4192-7_15. Methods Mol Biol. 2025. PMID: 39546208 Review. - Society of Surgical Oncology Breast Disease Site Working Group Statement on Bilateral Risk-Reducing Mastectomy: Indications, Outcomes, and Risks.
Singh P, Agnese DM, Amin M, Barrio AV, van den Bruele AB, Burke EE, Danforth DN Jr, Dirbas FM, Eladoumikdachi F, Fayanju OM, Kantor O, Kumar S, Lee MC, Matsen C, Nguyen TT, Ozmen T, Park KU, Plichta JK, Reyna C, Showalter SL, Styblo T, Tranakas N, Weiss A, Woodfin A, Laronga C, Boughey JC. Singh P, et al. Ann Surg Oncol. 2024 Nov 13. doi: 10.1245/s10434-024-16484-2. Online ahead of print. Ann Surg Oncol. 2024. PMID: 39538100 Review. - Double Heterozygous Pathogenic Variants in TP53 and CHEK2 in Boy with Undifferentiated Embryonal Sarcoma of the Liver.
Kuhlen M, Schaller T, Dintner S, Stadler N, Hofmann TG, Schmutz M, Claus R, Frühwald MC, Golas MM. Kuhlen M, et al. Int J Mol Sci. 2024 Oct 25;25(21):11489. doi: 10.3390/ijms252111489. Int J Mol Sci. 2024. PMID: 39519042 Free PMC article. - Germline DNA Damage Repair Gene Alterations in Patients with Metachronous Breast and Colorectal Cancer.
Villacis RAR, Côrtes L, Basso TR, do Canto LM, Souza JS, Aagaard MM, da Cruz Formiga MN, Aguiar S Jr, Achatz MI, Rogatto SR. Villacis RAR, et al. Int J Mol Sci. 2024 Sep 24;25(19):10275. doi: 10.3390/ijms251910275. Int J Mol Sci. 2024. PMID: 39408606 Free PMC article. - Micro-RNAs in breast cancer progression and metastasis: A chromatin and metabolic perspective.
Sikder S, Bhattacharya A, Agrawal A, Sethi G, Kundu TK. Sikder S, et al. Heliyon. 2024 Sep 20;10(19):e38193. doi: 10.1016/j.heliyon.2024.e38193. eCollection 2024 Oct 15. Heliyon. 2024. PMID: 39386816 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous